3
Announcements
Trials
Browse
Landscape
Status
No longer available
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
4
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Myeloid
1
Lymphoid
1
Conditions
Mastocytosis, Systemic
1
Leukemia, Myeloid, Acute
1
Leukemia, Mast-Cell
1
Interventions
venetoclax
3
fludarabine phosphate
3
fludarabine
3
navitoclax
2
ibrutinib
2
brexucabtagene autoleucel
2
axicabtagene ciloleucel
2
asparaginase erwinia chrysanthemi recombinant
2
Cyclophosphamide
2
zanubrutinib
1
tisagenlecleucel
1
tipifarnib
1
tafasitamab
1
sugemalimab
1
selinexor
1
plerixafor
1
pirtobrutinib
1
nilotinib
1
midostaurin
1
loncastuximab tesirine
1
idelalisib
1
glucarpidase
1
eryaspase
1
ceritinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Rituximab
1
Proton Pump Inhibitors
1
Mycophenolic Acid
1
Hydrocortisone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Expanded_access
×
midostaurin
×
Lymphoid
×
Clear all
NCT05219266
2024-06-28
Managed Access Programs for PKC412, Midostaurin
Novartis
No longer available